RxDoctor Payments Data

Amy Bright, PA

Physician Assistant · Golden, CONPI 1215407267

Payments from drug & device makers

$2,485in general payments, 2019–2025

Across 70 payments — averaging $35.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$373
  • Medtronic$284
  • Edwards Lifesciences$281
  • Novartis$238
  • Boston Scientific$217
  • E.r. Squibb & Sons, L.L.C.$154
  • plus $938 from 18 others

What the payments were for

  • Food & beverage$2,485100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,485 in reported general payments places this provider in the 85th percentile of 2,849 physician assistant providers in Colorado.

See all physician assistant providers in Colorado

Medicare billing

Part B allowed, 2024
$45,596
Medicare patients
319
Services billed
675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban115$93,463
EntrestoSacubitril/Valsartan28$41,576
XareltoRivaroxaban30$37,133
JardianceEmpagliflozin30$30,998
Repatha SureclickEvolocumab31$18,184
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$1,606
Metoprolol Succinate127$1,575
Valsartan23$910
Ranolazine ErRanolazine12$780
Torsemide22$547
Atorvastatin Calcium54$495
Amiodarone Hcl31$418
ClopidogrelClopidogrel Bisulfate56$361
Spironolactone58$328
Carvedilol35$302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$134$93,463115 claims
NovartisEntresto$238$41,57628 claims
Boehringer IngelheimJardiance$55$30,99830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,849 physician assistant providers in Colorado.

Other physician assistant in Golden

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →